• About
  • Subscribe
  • Advertise
  • Contact
Tuesday, June 17, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Business

FDA breakthrough for Australian bionic eye

by Staff Writer
February 8, 2022
in Business, Company updates & acquisitions, Local, News, Products
Reading Time: 2 mins read
A A
Bionic Vision Technologies CEO Dr Ash Attia with his company's bionic eye technology.

Bionic Vision Technologies CEO Dr Ash Attia with his company's bionic eye technology.

Share on FacebookShare on Twitter

Australia’s world-first Bionic Eye System has been granted designation as a Breakthrough Device by the Food and Drug Administration (FDA) in the US.

Developed by Bionic Vision Technologies (BVT), the Centre for Eye Research Australia, the Bionics Institute, CSIRO’s Data61 and the University of Melbourne, the groundbreaking technology aims to give functional vision to millions of people who have lost their sight due to retinitis pigmentosa (RP).

The late-stage RP market is estimated to be worth more than US$3.5 billion (AU$4.9 b).

The FDA’s Breakthrough Devices Program speeds up the review and assessment of medical devices which provide “more effective treatment” than any alternatives currently available.

“This is a significant achievement and a key milestone for BVT,” CEO Dr Ash Attia said.

The system consists of a wearable device and visual implant similar to cochlear hearing implants. Image BVT

“The life-changing bionic eye can be brought more quickly to the people who need it the most.”

According to BVT, the technology features tiny cameras that are embedded within a pair of glasses that send electrical signals to a wearable processor. The processor transmits to an implant behind the retina, delivering visual information to the blind person, giving them functional vision.

A recently published peer-reviewed two-year study focused on four Australians using the bionic eye. They reported being able to recognise their loved ones in a cafe, identify vacant chairs, arrange their washing, and identify surroundings such as traffic lights, cars, people, trees and street poles.

Meanwhile, the University of Melbourne has been awarded a $1.14m grant from the National Health and Medical Research Council (NHMRC) to work with BVT on the next generation bionic eye.

The funds will be used to develop and test a retinal implant with closed loop multichannel stimulation to further improve what patients can see and do.

In 2023, BVT will conduct a global pivotal study as the next step towards the commercialisation of its device.

“RP is a debilitating disease, and the impacts are just devastating,” Dr Attia said.

“We are all proud to be part of BVT and our entire team is excited by leading the world in a project to restore functional vision to those who have lost their precious sight.”

More reading

Aussie bionic eye project secures $2m cash injection

Human trials on the horizon for Sydney team’s bionic eye

Related Posts

The brand is renowned for “signature artisanal craftsmanship and precise engineering”. Image: Safilo.

Safilo launches Stuart Weitzman eyewear in Australia

by Staff Writer
June 17, 2025

Stuart Weitzman has expanded its global luxury brand footprint with a first eyewear collection available to Australian independent optical practices...

Studies show only about 17% of people are currently wearing lenses truly matching their visual sensitivity. Image: Rodenstock.

Understanding the concept of ‘visual sensitivity’

by Staff Writer
June 17, 2025

Even when a lens is designed identically for two different people, they can have a polarising visual experience. ALEX RIGBY...

The Eyerising device is reported to be the only red-light device with international regulatory approval outside of China. Image: Eyerising International.

Inclusion of red-light therapy in WSPOS 2025 Myopia Consensus Statement

by Myles Hume
June 16, 2025

Repeated low-level red-light (RLRL) therapy has been included in the 2025 Myopia Consensus Statement released by the World Society of...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited